Loperamide child-proof packaging
Executive Summary
Regulation to require child-resistant closures on antidiarrheal products containing 0.045 mg loperamide proposed by Consumer Product Safety Commission in Oct. 14 Federal Register notice. The reg would apply to vials of prescription capsules and OTC caplet and liquid forms. McNeil currently markets OTC Imodium A-D in child-resistant containers. However, CPSC noted that "other products may come on the market." Loperamide is structurally related to the opium alkyloids. The medical literature includes reports of 11 deaths of children under five due to loperamide poisoning, although most incidents involve "intentional administration of loperamide to children" in foreign countries, CPSC states. The reg will take effect 30 days after a final reg is published because currently marketed loperamide products already include child-resistant packaging, CPSC said. Comments are due by Dec. 28.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth